Immunoglobulin News and Research

RSS

Effectiveness of mRNA BNT162b2 COVID-19 vaccine in immunocompromised individuals

Israeli researchers evaluate the antibody response in ICPs to assess antibody-mediated immunity following vaccination with the Pfizer-BioNTech vaccine.

26 Oct 2021

Fermented soy product suppresses airway inflammation in animal models of asthma

Bronchial asthma causes symptoms such as wheezing and cough due to chronic airway inflammation, but there is no fundamental treatment for it, leaving a desire for new prevention and treatment methods.

26 Oct 2021

Sexually dimorphic placental antibody transfer during SARS-CoV-2 infection

In a paper recently published in the journal Science Translational Medicine by Bordt et al. (October 19th, 2021), maternal SARS-CoV-2 infections are studied with particular regard to maternal-fetal antibody transfer and virus-induced placental interferon responses, finding a sexually dimorphic response that results in lesser antibody transfer to the male fetus.

26 Oct 2021

How pregnancy influences SARS-CoV-2 immune response

A focus article published in Science Translational Medicine highlighted two recently published studies that investigated the response of pregnant women to natural infections and COVID-19 vaccines.

25 Oct 2021

A comparison between Pfizer/BioNTech's and Sinopharm's SARS-CoV-2 vaccines

Researchers compare antibody titers elicited the Pfizer‐BioNTech mRNA and the classic inactivated virus Sinopharm vaccines.

24 Oct 2021

Does previous SARS-CoV-2 infection affect vaccine-induced immunity?

Researchers report the binding and pseudo-neutralizing antibody titers elicited after patients had received either the Pfizer-BioNTech or AstraZeneca vaccines.

24 Oct 2021

Study shows immune profile heterogeneity amongst healthy adults

Researchers opted to use single-cell RNA-seq to observe single cells in detail as they encounter a specific antigen.

22 Oct 2021

Immune responses to SARS-CoV-2 infection and vaccination in patients with multiple sclerosis

A new study has focused on the immune response in pwMS undergoing anti-CD20 treatment.

21 Oct 2021

Children show lower seroconversion rates than adults with mild COVID-19

A new study finds that following mild COVID-19, children are more likely to remain seronegative than adults, irrespective of the viral load or symptom severity.

20 Oct 2021

New research on phagocytosis and SARS-CoV-2's spike protein

A new study showed that convalescent patient plasma and monoclonal anti-spike antibodies were able to induce phagocytosis at high antibody concentrations.

20 Oct 2021

The neutralization potential of nanobodies against SARS-CoV-2

A recent review describes the role of nanobodies as a new class of recombinant antibodies that are used in the treatment of COVID-19.

20 Oct 2021

SARS-CoV-2 antibodies detected in breast milk of vaccinated mothers

Now, a new medRxiv* preprint study finds mothers vaccinated either one of the messenger RNA (mRNA) vaccines transferred neutralizing antibodies and cytokines, including interferon-gamma (IFNγ), to a breastfeeding child. Additionally, the humoral response in breastmilk was effective in neutralizing four variants of concern.

18 Oct 2021

Factors contributing to a weak antibody response to the Pfizer COVID-19 vaccine

A new study discusses risk factors for the failure of seroconversion following full vaccination with the COVID-19 Pfizer vaccine.

18 Oct 2021

Common treatment for MIS-C patients likely works by depleting neutrophils

Intravenous immune globulin (IVIG) — a common treatment for multisystem inflammatory syndrome in children (MIS-C) — likely works by depleting immune cells called neutrophils, according to a recent study funded by the National Institutes of Health.

15 Oct 2021

SARS-CoV-2 induces tissue immune memory

A new study reports that the SARS-CoV-2 induces protective tissue memory that includes both humoral and cellular elements to protect specific tissue sites.

14 Oct 2021

Small portion of COVID-19 patients infectious long-term

In late December 2019, a novel pneumonia-like lung infection was reported in the Chinese province of Hubei. This, in turn, led to the ongoing coronavirus disease-19 (COVID-19) pandemic. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is closely related to SARS (Severe Acute Respiratory Syndrome) and MERS (the Middle East Respiratory Syndrome Coronavirus).

13 Oct 2021

How long does natural immunity produced by SARS-CoV-2 infection last?

A new study posted to the bioRxiv* preprint server followed the adaptive immune response in convalescent patients from Swedish and Italian cohorts—which had earlier shown long-lasting adaptive immune responses to the G614 strain—for 15 months. Here, specific antibody levels and neutralizing antibody titers were tested against variants of concern (VOCs).

12 Oct 2021

Vaccinated children induced significantly higher antibody titers than naturally SARS-CoV-2 infected children

A recent preprint discusses the antibody response to the nucleic acid vaccines against SARS-CoV-2 when administered to children aged 7-11 years.

12 Oct 2021

SARS-CoV-2 immune responses in nursing home residents after full vaccination with Pfizer-BioNTech COVID-19 vaccine

A new study assesses antibody and functional T-cell responses at 6 months after complete vaccination with the Pfizer-BioNTech vaccine.

11 Oct 2021

Research finds different antibody responses following COVID vaccination and natural infection

A new study published in the journal Nature attempted to investigate memory B cell evolution 5 months after vaccination with mRNA vaccines such as Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) in SARS-CoV-2 naïve individuals. The study explored various aspects of memory B cell antibody response like neutralizing response, affinity, epitope targeting, and neutralizing breadth.

10 Oct 2021